Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Mol Carcinog. 2016 Sep 5;56(3):833–848. doi: 10.1002/mc.22537

Figure 6.

Figure 6

Silibinin feeding decreases 22Rv1 xenograft growth in male athymic nude mice via targeting the lipid metabolism. (A) 22Rv1 xenografts were initiated in male athymic nude mice. Mice were administered either vehicle (CMC) or 200 mg/kg body weight dose of silibinin for 16 days. Tumor volume was measured on experimental day 0, 5, 9 and 16. Each value in the bar diagram is mean ± SEM of 12 xenografts. (B) Quantitative imaging end-points derived from FDG-PET, DWI, and DCE-MRI on untreated and silibinin-treated animals; *, p ≤ 0.001; $, p ≤ 0.05; (C) ADC maps showing low ADC values for silibinin-treated animals indicating no potential loss of cellularity upon the treatment; (D) decreased gadolinium kinetics on DCE-MRI revealing lower tumor vascularity in silibinin-treated animals; (E) PLS-DA regression analysis on comprehensive imaging and metabolomics date sets; (F) Variable Importance in Projection (VIP) scores from PLS-DA revealing the major discriminative end-points from in vivo silibinin treatment.